BBAPAP-39530; No. of pages: 2; 4C: Biochimica et Biophysica Acta xxx (2015) xxx–xxx
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta journal homepage: www.elsevier.com/locate/bbapap
Editorial
Editorial Medical Proteomics More than 20 years after the start of the proteomics era and 15 years after the competition of the human genome we are now looking at the outcomes of the field of Medical Proteomics. In this special issue of BBA PRO we present reviews and original papers which are dealing with the very special aspects of proteomics in the medical field. Thinking back 15 or 20 years we expected a revolution of new results with any new revolutionary technology introduced into the proteomics field. Indeed, various interdisciplinary approaches have been developed in proteomics, aimed at medical applications. Today, we know that the human population is very heterogeneous compared with inbred animals and a huge biological variance is a fact we have to deal with. Proteomics will help in the understanding of the physiological heterogeneity of the human being, and will be an essential approach to retrieve functional information from genomic data. Besides a further understanding of the physiological heterogeneity, the medical application of proteomics is an urgent need in this era too. The advent of novel therapeutic strategies including molecular targeting therapy and immunotherapy raised urgent needs of biomarkers, which will be a solution for disease heterogeneity. Proteomics has been expected to contribute to modern medicine through biomarker development. For this sake, a tight collaboration between proteomics experts, expert medical doctors, expert pathologists and bioinformatics is a must to reach our goal of better human health. We currently see, that our technology has reached the possibilities we have dreamed of for many years, and we are just starting to see that our efforts in our research are bringing fruits that we have expected for a long time. Although the visible results now are much higher than we thought when we started, we need an innovational approach to reach our goal. In this special issue, we intended to collect all of our current knowledge and expertise about medical proteomics, in order to overview our achievements and current status, and to establish the strategies toward our final goal, that is, a deep understanding of the biological issues of medicine and the better health and welfare of the human being Barbara Sitek, PhD assistant professor is a deputy director of Medical Proteom-Center at the Ruhr University of Bochum, Germany. B. Sitek studied biology (1995–2000) and made her diploma thesis in the Department of Animal Physiology. Her doctorate was performed within the Medical Proteome-Center (2004–2007) in the field of biomarker identification. Since 2007 B. Sitek has been a principal investigator of numerous grants from government. In 2010 she was appointed to an assistant professorship of proteome research. Her work group Clinical Proteomics deals with the development and application of methods for tackling clinical problems, with an emphasis on the identification of disease-specific biomarkers and therapeutic targets, as well as on the clarification of pathological associations on the protein level. On one hand, her group developed the methods for detecting disease-specific biomarkers in tissue or body fluids. On the other hand, they also devoted special attention to the validation of these proteins as biomarkers.
Helmut E. Meyer, Professor of Biochemistry, Director of the Biomedical Research Department, Leibniz Institute for Analytical Sciences, ISAS e.V., Dortmund, Germany. Helmut E. Meyer received his undergraduate degree in Biochemistry 1974 from the University of Tübingen, Germany and his Ph.D. in Biochemistry in 1976 from the Ruhr-Universität Bochum, Germany. He was a post-doctoral fellow at the Ruhr-Universität Bochum, Institute for Physiological Chemistry for one year and an employee of Roha Pharmaceutical Company, Bremen, Germany. From 1978 to 1984 he was a research fellow at the Diabetes Research Institute in Düsseldorf. In 1985 he became the leader of the Protein Analytical Group at the Institute for Physiological Chemistry at RuhrUniversität Bochum. He has been a lecturer for biochemistry in the Medical Faculty of the Ruhr-Universität Bochum since 1989. In 2002 he became the Director of the Medical Proteom-Center at the Ruhr-Universität Bochum, which is one of the world's leading institutes in proteome and protein analysis. His research interest covers all medical areas as well as natural scientific fundamentals. Since the beginning of 2014 he became the Director of the Biomedical Research Department of the Leibniz Institute for Analytical Sciences, ISAS e.V., Dortmund, Germany. Helmut E. Meyer is currently the treasurer of the German Proteomic Society.
Tadashi Kondo, MD, Ph.D. is Chief of the Division of Rare Cancer Research at the National Cancer Center (NCC), Tokyo, Japan. His interest lies in the field of translational cancer research that deals with various aspects of metastasis, recurrence, and resistance to treatment of malignant tumors. He targets novel disease backgrounds that lead to innovative therapy using multiple omics technologies and biobank resource. He has developed applications of proteomics for the best use of tumor tissues, such as those for laser microdissection and 2D-DIGE, and has constructed a cancer proteomics database (GeMDBJ Proteomics). Dr. Kondo earned his medical degree and doctorate from the Institute of Cellular and Molecular Biology at the Okayama University Medical School, Okayama, Japan. He completed his postdoctoral research fellowship at the Department of Pediatric Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA. Later, he served numerous positions as Section Head of the Cancer Proteomics Project (2001–2006), Project Leader of the Proteome Bioinformatics Project (2006–2010), and Chief of the Division of Pharmacoproteomics (2010–2014) at the NCC. In 2014, Dr. Kondo was appointed Chief of the Rare Cancer Research at the NCC. Dr. Kondo has a distinguished track record in translational research on malignancies of the respiratory tract, gastrointestinal tract, liver and biliary tract, and mesenchymal tissues. His extensive list of publications (over 100 peerreviewed journal articles and book chapters) and patents demonstrate his success as an accomplished scientist. As principal investigator, Dr. Kondo leads a laboratory that includes approximately 30 people and has constantly acquired grants from government and industry sponsors. In addition to bench translational research, he joins the Rare Cancer Center at the NCC to promote nation-wide networking of medical doctors and to support patients and their families.
http://dx.doi.org/10.1016/j.bbapap.2015.02.006 1570-9639/© 2015 Published by Elsevier B.V.
Please cite this article as: B. Sitek, et al., Editorial Medical Proteomics, Biochim. Biophys. Acta (2015), http://dx.doi.org/10.1016/ j.bbapap.2015.02.006
2
Editorial
Barbara Sitek Ruhr University of Bochum, Germany Corresponding author. Helmut E. Meyer Leibniz Institute for Analytical Sciences, ISAS e.V., Dortmund, Germany Corresponding author. Tadashi Kondo National Cancer Center (NCC), Tokyo, Japan Corresponding author.
Available online xxxx
Please cite this article as: B. Sitek, et al., Editorial Medical Proteomics, Biochim. Biophys. Acta (2015), http://dx.doi.org/10.1016/ j.bbapap.2015.02.006
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta journal homepage: www.elsevier.com/locate/bbapap
Editorial
Editorial Medical Proteomics More than 20 years after the start of the proteomics era and 15 years after the competition of the human genome we are now looking at the outcomes of the field of Medical Proteomics. In this special issue of BBA PRO we present reviews and original papers which are dealing with the very special aspects of proteomics in the medical field. Thinking back 15 or 20 years we expected a revolution of new results with any new revolutionary technology introduced into the proteomics field. Indeed, various interdisciplinary approaches have been developed in proteomics, aimed at medical applications. Today, we know that the human population is very heterogeneous compared with inbred animals and a huge biological variance is a fact we have to deal with. Proteomics will help in the understanding of the physiological heterogeneity of the human being, and will be an essential approach to retrieve functional information from genomic data. Besides a further understanding of the physiological heterogeneity, the medical application of proteomics is an urgent need in this era too. The advent of novel therapeutic strategies including molecular targeting therapy and immunotherapy raised urgent needs of biomarkers, which will be a solution for disease heterogeneity. Proteomics has been expected to contribute to modern medicine through biomarker development. For this sake, a tight collaboration between proteomics experts, expert medical doctors, expert pathologists and bioinformatics is a must to reach our goal of better human health. We currently see, that our technology has reached the possibilities we have dreamed of for many years, and we are just starting to see that our efforts in our research are bringing fruits that we have expected for a long time. Although the visible results now are much higher than we thought when we started, we need an innovational approach to reach our goal. In this special issue, we intended to collect all of our current knowledge and expertise about medical proteomics, in order to overview our achievements and current status, and to establish the strategies toward our final goal, that is, a deep understanding of the biological issues of medicine and the better health and welfare of the human being Barbara Sitek, PhD assistant professor is a deputy director of Medical Proteom-Center at the Ruhr University of Bochum, Germany. B. Sitek studied biology (1995–2000) and made her diploma thesis in the Department of Animal Physiology. Her doctorate was performed within the Medical Proteome-Center (2004–2007) in the field of biomarker identification. Since 2007 B. Sitek has been a principal investigator of numerous grants from government. In 2010 she was appointed to an assistant professorship of proteome research. Her work group Clinical Proteomics deals with the development and application of methods for tackling clinical problems, with an emphasis on the identification of disease-specific biomarkers and therapeutic targets, as well as on the clarification of pathological associations on the protein level. On one hand, her group developed the methods for detecting disease-specific biomarkers in tissue or body fluids. On the other hand, they also devoted special attention to the validation of these proteins as biomarkers.
Helmut E. Meyer, Professor of Biochemistry, Director of the Biomedical Research Department, Leibniz Institute for Analytical Sciences, ISAS e.V., Dortmund, Germany. Helmut E. Meyer received his undergraduate degree in Biochemistry 1974 from the University of Tübingen, Germany and his Ph.D. in Biochemistry in 1976 from the Ruhr-Universität Bochum, Germany. He was a post-doctoral fellow at the Ruhr-Universität Bochum, Institute for Physiological Chemistry for one year and an employee of Roha Pharmaceutical Company, Bremen, Germany. From 1978 to 1984 he was a research fellow at the Diabetes Research Institute in Düsseldorf. In 1985 he became the leader of the Protein Analytical Group at the Institute for Physiological Chemistry at RuhrUniversität Bochum. He has been a lecturer for biochemistry in the Medical Faculty of the Ruhr-Universität Bochum since 1989. In 2002 he became the Director of the Medical Proteom-Center at the Ruhr-Universität Bochum, which is one of the world's leading institutes in proteome and protein analysis. His research interest covers all medical areas as well as natural scientific fundamentals. Since the beginning of 2014 he became the Director of the Biomedical Research Department of the Leibniz Institute for Analytical Sciences, ISAS e.V., Dortmund, Germany. Helmut E. Meyer is currently the treasurer of the German Proteomic Society.
Tadashi Kondo, MD, Ph.D. is Chief of the Division of Rare Cancer Research at the National Cancer Center (NCC), Tokyo, Japan. His interest lies in the field of translational cancer research that deals with various aspects of metastasis, recurrence, and resistance to treatment of malignant tumors. He targets novel disease backgrounds that lead to innovative therapy using multiple omics technologies and biobank resource. He has developed applications of proteomics for the best use of tumor tissues, such as those for laser microdissection and 2D-DIGE, and has constructed a cancer proteomics database (GeMDBJ Proteomics). Dr. Kondo earned his medical degree and doctorate from the Institute of Cellular and Molecular Biology at the Okayama University Medical School, Okayama, Japan. He completed his postdoctoral research fellowship at the Department of Pediatric Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA. Later, he served numerous positions as Section Head of the Cancer Proteomics Project (2001–2006), Project Leader of the Proteome Bioinformatics Project (2006–2010), and Chief of the Division of Pharmacoproteomics (2010–2014) at the NCC. In 2014, Dr. Kondo was appointed Chief of the Rare Cancer Research at the NCC. Dr. Kondo has a distinguished track record in translational research on malignancies of the respiratory tract, gastrointestinal tract, liver and biliary tract, and mesenchymal tissues. His extensive list of publications (over 100 peerreviewed journal articles and book chapters) and patents demonstrate his success as an accomplished scientist. As principal investigator, Dr. Kondo leads a laboratory that includes approximately 30 people and has constantly acquired grants from government and industry sponsors. In addition to bench translational research, he joins the Rare Cancer Center at the NCC to promote nation-wide networking of medical doctors and to support patients and their families.
http://dx.doi.org/10.1016/j.bbapap.2015.02.006 1570-9639/© 2015 Published by Elsevier B.V.
Please cite this article as: B. Sitek, et al., Editorial Medical Proteomics, Biochim. Biophys. Acta (2015), http://dx.doi.org/10.1016/ j.bbapap.2015.02.006
2
Editorial
Barbara Sitek Ruhr University of Bochum, Germany Corresponding author. Helmut E. Meyer Leibniz Institute for Analytical Sciences, ISAS e.V., Dortmund, Germany Corresponding author. Tadashi Kondo National Cancer Center (NCC), Tokyo, Japan Corresponding author.
Available online xxxx
Please cite this article as: B. Sitek, et al., Editorial Medical Proteomics, Biochim. Biophys. Acta (2015), http://dx.doi.org/10.1016/ j.bbapap.2015.02.006
